Wipro Strengthens Middle East Presence with New Regional Headquarters in Riyadh
BENGALURU, India & RIYADH, Saudi Arabia--(BUSINESS WIRE)--Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading AI-powered technology services and consulting company, announced the relocation of its Middle East regional headquarters from Al Khobar to Riyadh, Saudi Arabia. The new office in Riyadh was inaugurated in a ceremony attended by the Wipro executive team, employees, and customers. This is the latest addition to Wipro's growing presence in the region, which includes offices in Riyadh, Al Khobar, Jeddah, and Jubail.
'The inauguration of Wipro's new regional headquarters in Riyadh marks a significant milestone that contributes to accelerating the growth of the Kingdom's digital economy,' said Mohammed AlRobayan, Deputy Minister for Technology at the Ministry of Communications and Information Technology (MCIT). 'This also underscores the attractiveness of Saudi Arabia's digital business environment. We value the company's investment in developing national competencies, in line with the objectives of Saudi Vision 2030 and enhancing the Kingdom's position as a global technology hub.'
In addition to this new office opening, Wipro recently signed a Memorandum of Understanding (MoU) with Prince Mohammad Bin Fahd University (PMU) to establish a Center of Excellence (CoE) in Riyadh. This partnership aims to upskill local talent by providing academic training in advanced technologies, hands-on experience, and access to Wipro's resources. The CoE will focus on equipping young Saudi nationals with future-ready skills, creating a talent pool that can add value to organizations and the kingdom.
'The establishment of our new regional headquarters in Riyadh reaffirms our commitment to supporting the dynamic business landscape in the Kingdom of Saudi Arabia,' said Vinay Firake, CEO – Asia Pacific, India, Middle East & Africa (APMEA), Wipro Limited. 'This strategic move, combined with our ongoing involvement in supporting the goals of the Kingdom, aligns with our vision of driving sustained growth and a future-ready workforce in the region. This commitment is strengthened by the recent appointment of Mohamed Mousa as our new Managing Director for Wipro Middle East out of our Riyadh headquarters, which will further advance our decades-long presence in the Middle East.'
About Wipro Limited
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading AI-powered technology services and consulting company focused on building innovative solutions that address clients' most complex digital transformation needs. Leveraging our holistic portfolio of capabilities in consulting, design, engineering, and operations, we help clients realize their boldest ambitions and build future-ready, sustainable businesses. With over 230,000 employees and business partners across 65 countries, we deliver on the promise of helping our clients, colleagues, and communities thrive in an ever-changing world. For additional information, visit us at www.wipro.com.
Forward-Looking Statements
The forward-looking statements contained herein represent Wipro's beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro's control. Such statements include, but are not limited to, statements regarding Wipro's growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry.
Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
an hour ago
- CNBC
Stock futures are near flat as U.S.-China trade talks continue, May inflation report looms: Live updates
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., March 19, 2025. Brendan Mcdermid | Reuters Stock futures were little changed on Tuesday evening as investors awaited progress on trade policy talks between the U.S. and China. They also anticipated the release of May's consumer inflation report. Futures tied to the S&P 500 slipped 0.07%, while Nasdaq 100 futures pulled back 0.05%. Dow Jones Industrial Average futures lost 28 points, or 0.07%. Trade talks between U.S. and Beijing officials continued for a second day in London on Tuesday. U.S. Treasury Secretary Scott Bessent said he would be departing the ongoing trade talks with China, but U.S. Commerce Secretary Howard Lutnick and U.S. Trade Representative Jamieson Greer would remain to continue the negotiations. Discussions could extend into Wednesday if needed, Lutnick said earlier. The discussions are a key focus for investors and a broader market that remains jittery toward any jolts on trade policy. Both China and the U.S. previously agreed to temporarily pause high tariffs on one another in May, although a fully ironed out agreement has yet to materialize. In regular trading on Tuesday, the S&P 500 rose about 0.6%, posting a third straight positive session. The broad market index sits less than 2% off the high it notched in February. The Nasdaq Composite added 0.6% on Tuesday, while the 30-stock Dow climbed 0.3%. Even as stocks have been resurging, tariff fears and rising bond yields could hang over the market, according to Deutsche Bank. "One key concern is that the Trump administration, buoyed by the market rebound, may resume aggressive tariff rhetoric—potentially triggering renewed retaliation from China and Europe, as seen earlier this year," the firm's group chief economist David Folkerts-Landau said in a Tuesday note. "At the same time, rising long-end bond yields are amplifying fiscal concerns globally, particularly given plans for expanded deficits across multiple major economies," he added. "With several countries already on unsustainable debt paths, the events of 2025 may have accelerated an inevitable reckoning." Investors will get further insight into the U.S. economy on Wednesday morning as the Bureau of Labor Statistics rolls out May's reading of the consumer price index. Economists polled by Dow Jones call for a 0.2% month-over-month increase, while headline CPI is anticipated to have grown 2.4% from 12 months earlier. A hot report could spook investors who are already on edge over inflationary pressures. "Ultimately this report is not expected to cause any significant changes to the Fed's current wait and see approach when it comes to setting rates," said Sam Millette, director of fixed income at Commonwealth Financial Network. "With that being said, we'll have to wait and see if the report shows the anticipated modest rise in price pressure that's expected or if there are any surprises in store for investors." On the earnings front Wednesday, traders will look for reports from Chewy and Oracle .
Yahoo
an hour ago
- Yahoo
Byline Bancorp, Inc. Announces Commencement of Secondary Public Offering of Common Stock and Concurrent Share Repurchase
CHICAGO, June 10, 2025--(BUSINESS WIRE)--Byline Bancorp, Inc. ("Byline" or the "Company") (NYSE: BY) announced today that the Estate of Daniel L. Goodwin (the "Estate") and Equity Shares Investors, LLC, an affiliate of the Estate, the selling stockholders of the Company (the "Selling Stockholders"), are offering for sale to the public a total of 4,282,210 shares (the "Offered Shares") of the Company's common stock (the "Secondary Offering"). The Company is not offering or selling any shares of its common stock in the Secondary Offering and will not receive any proceeds from the sale of its shares of common stock in the Secondary Offering. In addition, the Company intends to purchase from the underwriter between $5 million and $10 million of the shares of common stock in the Secondary Offering (the "Share Repurchase"), at a price per share equal to the price per share to be paid by the underwriter to the Selling Stockholders. The Company intends to execute the Share Repurchase as part of its existing share repurchase program authorized on January 1, 2025. The underwriter will not receive any discount or commission in respect of the shares of common stock being purchased by the Company in the Share Repurchase. The Share Repurchase is conditioned upon the completion of the Secondary Offering, as well as the satisfaction of customary closing conditions, and is expected to close concurrently with the completion of the Secondary Offering. Certain of the Company's directors have indicated an interest in purchasing up to an aggregate $3.1 million in shares of common stock in the Secondary Offering at the public offering price and on the same terms as the other purchasers in the Secondary Offering. J.P. Morgan is serving as the sole underwriter for the Secondary Offering. An automatically effective shelf registration statement on Form S-3 relating to the shares of the Company's common stock subject to the Secondary Offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and is available on the SEC's website at The Secondary Offering will be made only by means of a prospectus supplement and accompanying prospectus that forms a part of the registration statement, copies of which may be obtained, when available, by request from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@ and postsalemanualrequests@ This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. About Byline Bancorp, Inc. Headquartered in Chicago, Byline Bancorp, Inc. is the parent company of Byline Bank, a full service commercial bank serving small- and medium-sized businesses, financial sponsors, and consumers. Byline Bank has approximately $9.6 billion in assets and operates 46 branch locations throughout the Chicago and Milwaukee metropolitan areas. Byline Bank offers a broad range of commercial and community banking products and services including small ticket equipment leasing solutions and is one of the top Small Business Administration lenders in the United States. Forward-Looking Statements This press release may contain "forward-looking statements" including statements concerning the size and terms of the Secondary Offering and the size and terms of the Share Repurchase. All statements other than statements of historical facts contained in this press release may be forward-looking statements. In some cases, you can identify the forward-looking statements by the use of words such as "may," "could," "should," "would," "expect," "plan," "anticipate," "intend," "forecast," "believe," "estimate," "predict," "propose," "potential," "continue," "scheduled," or the negative of these terms or other comparable terminology. These forward-looking statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include but are not limited to those set forth in the periodic reports Byline files with the SEC and those described in the registration statement and the prospectus supplement and accompanying prospectus related to the Secondary Offering. All forward-looking statements included in this press release are made only as of the date of this press release. New factors emerge from time to time, and it is not possible for us to predict all of these factors. Further, we cannot assess the impact of each such factor on our business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement. We expressly disclaim any obligation to update or revise any forward-looking statements, whether because of future events, new information, a change in our views or expectations, or otherwise. We make no prediction or statement about the performance of our common stock. View source version on Contacts Contact For Byline Bancorp, Inc.: Investors / Media: Brooks O. RennieHead of Investor RelationsByline Bank(312) 660-5805brennie@
Yahoo
an hour ago
- Yahoo
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ("Philochem'), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. ('RayzeBio'), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated with the OncoACP3 diagnostic has been promising, displaying selective tumour uptake and long residence time with minimal healthy tissue uptake. IND-enabling activities to support the application for a Phase I therapeutic study with 225Ac-OncoACP3 are ongoing. Prof. Dr. Dario Neri, CEO and CSO of Philogen, commented: 'We are delighted to enter into this new collaboration with RayzeBio, a leader in the field of radiopharmaceutical medicines. This partnership will focus on the development and commercialization of OncoACP3 for both diagnostic and therapeutic applications in prostate cancer. OncoACP3 is a best-in-class targeting agent with the potential to become a breakthrough treatment in this field. This collaboration reflects our shared commitment to translating scientific innovation into meaningful clinical solutions, making OncoACP3 therapies widely available to patients in need.' Ben Hickey, President, RayzeBio commented: 'This collaboration with Philochem enhances our leadership in the rapidly advancing radiopharmaceuticals space, consistent with our strategy to bring forward best-in-class RPT candidates. OncoACP3, with its initial encouraging safety profile, provides a differentiated entry for Bristol Myers Squibb and RayzeBio into the prostate cancer arena, building on our leadership in actinium-based RPT development. This agreement is a significant milestone for RayzeBio and our goal to deliver radiopharmaceuticals to patients.' Under the terms of the agreement, Philochem will receive an up-front payment of $350m and up to $1.0bn in development, regulatory and commercial milestones. The company will also receive mid-single to low double-digit royalties payable on Global Net Sales of both Therapeutic and Diagnostic agents of OncoACP3. The closing of the transaction is subject to regulatory approvals and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2025. For Philochem, Centerview Partners UK LLP is acting as exclusive financial advisor and Cooley LLP is acting as exclusive legal counsel. About Philogen group Philogen is an Italian-Swiss group active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Philogen's mission is to discover, develop and market innovative pharmaceuticals for the treatment of diseases of high unmet need. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. FOR MORE INFORMATION Philogen - Investor Relations IR@ - Emanuele Puca | Investor RelationsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
